Totals
- Total revenue
- $511,468,181
- Total expenses
- $511,468,181
- Contributions and grants received
- $511,468,181
- Grants paid
- $511,468,181
- Program service revenue
- $0
- Investment income
- $0
- Other revenue
- $0
- Total assets, end of year
- $0
- Total liabilities, end of year
- $0
- Net assets or fund balances, end of year
- $0
- Program services expenses (Part IX)
- $511,468,181
- Management and general expenses
- $0
- Fundraising expenses
- $0
- Program service expenses (Part III)
- $511,468,181
Program services were 100.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1a · Federated campaigns
$0
-
1b · Membership dues
$0
-
1c · Fundraising events
$0
-
1d · Related organizations
$0
-
1e · Government grants (contributions)
$0
-
1f · All other contributions, gifts and grants
$511,468,181
-
1g · Noncash contributions included above
$0
-
6c · Rental income or loss
real property $0 · personal property $0
-
7c · Gain or loss
securities $0 · other assets $0
-
8a · Fundraising events: contributions included on line 1c
$0
-
11e · Other revenue, total
$0
Functional expenses
Part IX, the statement of functional expenses.
-
3 · Grants to foreign organizations and individuals
total $511,468,181 · program services $511,468,181
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $0 · end of year $0
-
2 · Savings and temporary cash investments
beginning of year $0 · end of year $0
-
3 · Pledges and grants receivable
beginning of year $0 · end of year $0
-
4 · Accounts receivable
beginning of year $0 · end of year $0
-
5 · Loans and receivables from officers and key people
beginning of year $0 · end of year $0
-
6 · Loans and receivables from disqualified persons
beginning of year $0 · end of year $0
-
7 · Other notes and loans receivable
beginning of year $0 · end of year $0
-
8 · Inventories for sale or use
beginning of year $0 · end of year $0
-
9 · Prepaid expenses and deferred charges
beginning of year $0 · end of year $0
-
11 · Investments: publicly traded securities
beginning of year $0 · end of year $0
-
12 · Investments: other securities
beginning of year $0 · end of year $0
-
13 · Investments: program-related
beginning of year $0 · end of year $0
-
14 · Intangible assets
beginning of year $0 · end of year $0
-
15 · Other assets
beginning of year $0 · end of year $0
-
17 · Accounts payable and accrued expenses
beginning of year $0 · end of year $0
-
18 · Grants payable
beginning of year $0 · end of year $0
-
19 · Deferred revenue
beginning of year $0 · end of year $0
-
20 · Tax-exempt bond liabilities
beginning of year $0 · end of year $0
-
21 · Escrow or custodial account liability
beginning of year $0 · end of year $0
-
22 · Loans and payables to officers and key people
beginning of year $0 · end of year $0
-
23 · Secured mortgages and notes payable
beginning of year $0 · end of year $0
-
24 · Unsecured notes and loans payable
beginning of year $0 · end of year $0
-
25 · Other liabilities
beginning of year $0
-
27 · Net assets without donor restrictions
beginning of year $0 · end of year $0
-
28 · Net assets with donor restrictions
beginning of year $0 · end of year $0
Mission and programs · 2023
Mission
As a supporting organization, support the global health efforts of The Task Force for Global Health, Inc. by principally receiving donated phamaceuticals and coordinating the shipment to designated countries for the treatment of blinding trachoma, river blindness and vaccine preventable diseases.
Activities or mission (Part I)
As a supporting organization, provide support to the global health initiatives of The Task Force for Global Health,Inc.
-
The International Trachoma Initiative (ITI) works tirelessly for a world free from trachoma. ITI contributes to eliminating trachoma as a public health threat by stewarding Pfizer's donation of azithromycin to treat and prevent the condition; building and strengthening partnerships to accelerate progress; and developing innovative tools to share data. Between September 2023 and August 2024, ITI organized just-in-time shipments of 33.3 million treatments for trachoma to be distributed at MDAs in 15 countries. As of August 2024, ITI has shipped more than 1.073 billion treatments to trachoma-endemic countries since the program's inception in 1999. ITI continued its data management support for Tropical Data, a free mobile phone-based service to support trachoma programs as they conduct prevalence surveys, providing them with robust data for decision-making on where antibiotic treatments are needed and where they can be stopped. Since its inception in February 2016, Tropical Data has supported over 3,823 surveys across 52 countries. As a key player in the global trachoma community, there have been tremendous achievements in reducing the population at risk of blindness from trachoma from an estimated 1.2 billion people in 2000 to 103.2 million in April 2024 according to the World Health Organization's (WHO) Weekly Epidemiological Record (WER). ITI will continue to work smarter so that the dream of a trachoma-free world becomes a reality.
Expenses $458,632,706 · Revenue $458,632,706
-
Mectizan Donation Program Accomplishments In 2024, 406.1 million Mectizan treatments were approved for mass drug administration (MDA) for onchocerciasis and lymphatic filariasis (LF) elimination in 44 countries and territories. The breakdown of treatments approved is as follows: (a) 274.1 million for onchocerciasis only including 63 million treatments approved to implement a second round of treatment in 9 countries (Burkina Faso, DRC, Ethiopia, Ghana, Malawi, Nigeria, Tanzania, Togo, and Uganda). (b) 36.2 million for onchocerciasis & LF co-endemic communities. (c) 95.7 million for LF only, of which 52.8 million were approved for 14 countries implementing triple therapy with ivermectin, DEC, and albendazole (IDA). By the end of 2024, cumulatively, the number of Mectizan 3mg tablets shipped since the inception of the program reached 13.9 billion or 4.94 billion treatments. The 5 billionth treatment shipped will be reached in early 2025, a very exciting milestone that the Mectizan Donation Program (MDP) will celebrate with Merck & Co., Inc. and other partners working to eliminate these diseases. Timor Leste was validated by WHO for achieving the elimination of LF as a public health problem, the first country to achieve elimination using triple therapy with the WHO-recommended triple therapy strategy: ivermectin, DEC and albendazole (IDA). A press release was issued by MDP to congratulate the country. MDP supported WHO-HQ to prepare a request to be submitted to Merck for Mectizan donation to extend the donation of Mectizan for - triple therapy - or IDA (ivermectin, diethylcarbamazine, and albendazole. The application was submitted to Merck in November 2024 for consideration. MDP also supported WHO, country partners, and others in identifying challenges and creating solutions to ensure onchocerciasis and lymphatic filariasis remain on track to meet the goals established in the WHO 2021-2030 Road Map. A robust communications and advocacy plan including an annual report, social media, video production, and e-newsletter was implemented to share progress and relevant developments with partners. Our film - Eliminating Disease with Mectizan - produced in 2023 (renamed - The Pill That's Changed Millions of Lives) was entered by the producer in the 2024 Smiley Charity Awards, a high-profile award in the UK for non-profit causes. The film was selected as a finalist in the - Corporate Cause - and SDG 3 categories. The film did not win the award; however, this increased visibility for the donation of Mectizan and efforts to eliminate onchocerciasis and lymphatic filariasis.
Expenses $52,835,475 · Revenue $52,835,475
As filed on the 2023 return.
Listed in Part VII
-
Patrick O'Carroll
Chairman
- Total calculated
- $411,644
- From this org
- $0
- From related orgs
- $411,644
- Other
- $0
- Hours/week
- 1 + 39 related
Schedule J breakdown matched by us
- Base
- $0 + $380,636 related
- Bonus
- $0
- Other
- $0
- Deferred
- $0 + $29,700 related
- Nontaxable benefits
- $0 + $1,308 related
- Filer's total
- $0 + $411,644 related
-
Mark McKinlay
Officer
- Total calculated
- $387,309
- From this org
- $0
- From related orgs
- $387,309
- Other
- $0
- Hours/week
- 1 + 39 related
Schedule J breakdown matched by us
- Base
- $0 + $316,424 related
- Bonus
- $0
- Other
- $0
- Deferred
- $0 + $28,960 related
- Nontaxable benefits
- $0 + $41,925 related
- Filer's total
- $0 + $387,309 related
-
William P Nichols
Officer
- Total calculated
- $339,114
- From this org
- $0
- From related orgs
- $339,114
- Other
- $0
- Hours/week
- 1 + 39 related
Schedule J breakdown matched by us
- Base
- $0 + $310,032 related
- Bonus
- $0
- Other
- $0
- Deferred
- $0 + $27,903 related
- Nontaxable benefits
- $0 + $1,179 related
- Filer's total
- $0 + $339,114 related
-
Daniel N Martins
Secretary
- Total calculated
- $253,744
- From this org
- $0
- From related orgs
- $253,744
- Other
- $0
- Hours/week
- 1 + 39 related
Schedule J breakdown matched by us
- Base
- $0 + $182,089 related
- Bonus
- $0 + $9,194 related
- Other
- $0
- Deferred
- $0 + $16,825 related
- Nontaxable benefits
- $0 + $45,636 related
- Filer's total
- $0 + $253,744 related
-
Ellen Wild
Treasurer
- Total calculated
- $227,921
- From this org
- $0
- From related orgs
- $227,921
- Other
- $0
- Hours/week
- 1 + 39 related
Schedule J breakdown matched by us
- Base
- $0 + $201,573 related
- Bonus
- $0 + $7,000 related
- Other
- $0
- Deferred
- $0 + $18,274 related
- Nontaxable benefits
- $0 + $1,074 related
- Filer's total
- $0 + $227,921 related
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
None.
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- Schedule J, Part I, Line 3
- The organization does not have employees but has officers who are paid by the related organization
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
No itemized grants to organizations on this return.
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $511,468,181
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| East Asia and the Pacific | 0 | 0 | Program Services | Donation of zithromax drug for the treatment of blinding trachoma | $5,403,353 |
| Middle East and North Africa | 0 | 0 | Program Services | Donation of zithromax drug for the treatment of blinding trachoma. | $11,474,201 |
| Sub-Saharan Africa | 0 | 0 | Program Services | Donation of zithromax drug for the treatment of blinding trachoma. | $441,755,152 |
| East Asia and the Pacific | 0 | 0 | Program Services | Donation of mectizan drug for the treatment of lymphatic filariasis. | $2,663,535 |
| South America | 0 | 0 | Program Services | Donation of mectizan drug for the treatment of lymphatic filariasis. | $384,405 |
| South Asia | 0 | 0 | Program Services | Donation of mectizan drug for the treatment of lymphatic filariasis. | $25,009,845 |
| Sub-Saharan Africa | 0 | 0 | Program Services | Donation of mectizan drug for the treatment of lymphatic filariasis. | $24,683,190 |
| Central America and the Caribbean | 0 | 0 | Program Services | Donation of mectizan drug for the treatment of lymphatic filariasis. | $94,500 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| Central America and the Caribbean | $0 | 0 | $94,500 | Mectizan drug | Lower of market or donor's cost. |
| East Asia and the Pacific | $0 | N/A | $8,066,888 | Drug donation - mectizan and zithromax | Lower of market or donor's costs |
| Middle East and North Africa | $0 | N/A | $11,474,201 | Donated drugs - zithromax | Lower of market or donor's cost |
| South America | $0 | N/A | $384,405 | Drug donation - Mectizan | Lower of market or donor's cost |
| South Asia | $0 | N/A | $25,009,845 | Drug donation - Mectizan | Lower of market or donor's cost |
| Sub-Saharan Africa | $0 | N/A | $466,438,342 | Drug donation - mectizan and zithromax | Lower of market or donor's cost |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 34
- Other grantees (Part II line 3)
- 0
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- Yes
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
The Task Force for Global Health Inc
501(c)(3) · Management and distribution of donated medicines · GA
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 30 April 2025
- IRS schema version
- 2023v6.0
- Source object
- 202511569349301426
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.